Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2012, Article ID 195484, 10 pages
http://dx.doi.org/10.1155/2012/195484
Review Article

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma

1Department of Transplant Oncohematology, Perugia University, S. Maria, Terni, Italy
2Faculty of Medicine, Perugia University, S. Maria, Terni, Italy

Received 15 October 2011; Accepted 15 November 2011

Academic Editor: Ian Magrath

Copyright © 2012 Marco Gunnellini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Tilly and M. Dreyling, “Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 21, no. 5, pp. v172–v174, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. P. Boffetta, “Epidemiology of adult non-Hodgkin lymphoma,” Annals of Oncology, vol. 22, supplement 4, pp. iv27–iv31, 2011. View at Google Scholar
  3. R. I. Fisher, E. R. Gaynor, S. Dahlberg et al., “Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma,” New England Journal of Medicine, vol. 328, no. 14, pp. 1002–1006, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. A. Shipp, D. P. Harrington, J. R. Andersen et al., “A predictive model for aggressive non-Hodgkin's lymphoma,” New England Journal of Medicine, vol. 329, no. 14, pp. 987–994, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. C. Traullé and B. B. Coiffier, “Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma,” Future Oncology, vol. 1, no. 3, pp. 297–306, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. B. Coiffier, E. Lepage, J. Brière et al., “Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma,” New England Journal of Medicine, vol. 346, no. 4, pp. 235–242, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. P. Feugier, A. Van Hoof, C. Sebban et al., “Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d'etude des lymphomes de l'adulte,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4117–4126, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. Pfreundschuh, L. Trümper, A. Österborg et al., “CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group,” Lancet Oncology, vol. 7, no. 5, pp. 379–391, 2006. View at Publisher · View at Google Scholar · View at PubMed
  9. L. H. Sehn, B. Berry, M. Chhanabhai et al., “The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP,” Blood, vol. 109, no. 5, pp. 1857–1861, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. M. Ziepert, D. Hasenclever, E. Kuhnt et al., “Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era,” Journal of Clinical Oncology, vol. 28, no. 14, pp. 2373–2380, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. T. Philip, C. Guglielmi, A. Hagenbeek et al., “Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma,” New England Journal of Medicine, vol. 333, no. 23, pp. 1540–1545, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. L. F. Verdonck, W. L. J. Van Putten, A. Hagenbeek et al., “Comparison of chop chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma,” New England Journal of Medicine, vol. 332, no. 16, pp. 1045–1051, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. M. Martelli, M. Vignetti, P. L. Zinzani et al., “High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study,” Journal of Clinical Oncology, vol. 14, no. 2, pp. 534–542, 1996. View at Google Scholar · View at Scopus
  14. C. Haioun, E. Lepage, C. Gisselbrecht et al., “Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d'etude des lymphomes de l'adulte study,” Journal of Clinical Oncology, vol. 18, no. 16, pp. 3025–3030, 2000. View at Google Scholar · View at Scopus
  15. H. C. Kluin-Nelemans, V. Zagonel, A. Anastasopoulou et al., “Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study,” Journal of the National Cancer Institute, vol. 93, no. 1, pp. 22–30, 2001. View at Google Scholar · View at Scopus
  16. N. Milpied, E. Deconinck, F. Gaillard et al., “Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support,” New England Journal of Medicine, vol. 350, no. 13, pp. 1287–1295, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. A. M. Gianni, M. Bregni, S. Siena et al., “High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma,” New England Journal of Medicine, vol. 336, no. 18, pp. 1290–1297, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. G. Santini, L. Salvagno, P. Leoni et al., “VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group,” Journal of Clinical Oncology, vol. 16, no. 8, pp. 2796–2802, 1998. View at Google Scholar · View at Scopus
  19. C. Gisselbrecht, E. Lepage, T. Molina et al., “Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma,” Journal of Clinical Oncology, vol. 20, no. 10, pp. 2472–2479, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. U. Kaiser, I. Uebelacker, U. Abel et al., “Randomized study to evaluate the use of high-dose therapy as part of primary treatment for aggressive lymphoma,” Journal of Clinical Oncology, vol. 20, no. 22, pp. 4413–4419, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Martelli, F. Gherlinzoni, A. De Renzo et al., “Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial,” Journal of Clinical Oncology, vol. 21, no. 7, pp. 1255–1262, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Olivieri, G. Santini, C. Patti et al., “Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG,” Annals of Oncology, vol. 16, no. 12, pp. 1941–1948, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. U. Vitolo, A. M. Liberati, M. G. Cabras et al., “High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi” randomized trial,” Haematologica, vol. 90, no. 6, pp. 793–801, 2005. View at Google Scholar · View at Scopus
  24. D. C. Betticher, G. Martinelli, J. A. Radford et al., “Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL),” Annals of Oncology, vol. 17, no. 10, pp. 1546–1552, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. D. C. Linch, L. Yung, P. Smith et al., “Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL: research paper,” British Journal of Haematology, vol. 149, no. 2, pp. 237–243, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, WHO Press, 4th edition, 2008.
  27. C. Tarella, M. Zanni, M. Di Nicola et al., “Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi),” Leukemia, vol. 21, no. 8, pp. 1802–1811, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. U. Vitolo, A. Chiappella, E. Angelucci et al., “Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study,” Haematologica, vol. 94, no. 9, pp. 1250–1258, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. M. S. Dilhuydy, T. Lamy, C. Foussard et al., “Front-line high-dose chemotherapy with Rituximab showed excellent long-term survival in adults with aggressive large B-cell lymphoma: final results of a phase II GOELAMS study,” Biology of Blood and Marrow Transplantation, vol. 16, no. 5, pp. 672–677, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. O. Fitoussi, K. Belhadj, N. Mounier et al., “Survival impact of rituximab combined with ACVBP and upfront consolidative autotransplantation in high risk diffuse large B-cell lymphoma for GELA,” Haematologica, vol. 96, pp. 1136–1143, 2011. View at Publisher · View at Google Scholar · View at PubMed
  31. P. J. Still, J. M. Unger, J. Cook et al., “Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma,” Journal of Clinical Oncology, vol. 29, abstract a8001, 2011. View at Google Scholar
  32. U. Vitolo, A. Chiappella, E. Brusamolino et al., “A randomized multicentre phase III study for first line treatment of young patients with high-risk (aaIPI 2-3) diffuse large B-cell lymphoma (DLBCL): Rituximab ® plus dose-dense chemotherapy CHOP14/megaCHOP14 with or without intensified high-dose chemotheraly (HDC) and autologous stem cell transplantation (ASCT). Results of DLCL04 trial od Italian Lymphoma Foundation (FIL),” Annals of Oncology, vol. 22, supplement 4, a072, p. iv106, 2011. View at Google Scholar
  33. C. Guglielmi, F. Gomez, T. Philip et al., “Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the parma trial,” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3264–3269, 1998. View at Google Scholar · View at Scopus
  34. J. Y. Blay, F. Gomez, C. Sebban et al., “The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial,” Blood, vol. 92, no. 10, pp. 3562–3568, 1998. View at Google Scholar · View at Scopus
  35. P. A. Hamlin, A. D. Zelenetz, T. Kewalramani et al., “Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma,” Blood, vol. 102, no. 6, pp. 1989–1996, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. T. Kewalramani, A. D. Zelenetz, S. D. Nimer et al., “Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma,” Blood, vol. 103, no. 10, pp. 3684–3688, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. M. Sieniawski, O. Staak, J. P. Glossmann et al., “Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma,” Annals of Hematology, vol. 86, no. 2, pp. 107–115, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. E. Vellenga, W. L. J. Van Putten, M. B. Van 't Veer et al., “Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial,” Blood, vol. 111, no. 2, pp. 537–543, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. N. Mounier, C. Canals, C. Gisselbrecht et al., “High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow transplantation registry,” Biology of Blood and Marrow Transplantation. In press. View at Publisher · View at Google Scholar · View at PubMed
  40. A. Martín, E. Conde, M. Arnan et al., “R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study,” Haematologica, vol. 93, no. 12, pp. 1829–1836, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. T. S. Fenske, P. N. Hari, J. Carreras et al., “Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma,” Biology of Blood and Marrow Transplantation, vol. 15, no. 11, pp. 1455–1464, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. C. Gisselbrecht, B. Glass, N. Mounier et al., “Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era,” Journal of Clinical Oncology, vol. 28, no. 27, pp. 4184–4190, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. I. F. Khouri, R. M. Saliba, C. Hosing et al., “Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas,” Journal of Clinical Oncology, vol. 23, no. 10, pp. 2240–2247, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. O. W. Press, J. F. Eary, F. R. Appelbaum et al., “Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support,” New England Journal of Medicine, vol. 329, no. 17, pp. 1219–1224, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. A. Krishnan, A. Nademanee, H. C. Fung et al., “Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 26, no. 1, pp. 90–95, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. J. N. Winter, D. J. Inwards, S. Spies et al., “Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 27, no. 10, pp. 1653–1659, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. A. A. Alizadeh, M. B. Eisen, R. E. Davis et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling,” Nature, vol. 403, no. 6769, pp. 503–511, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. A. Rosenwald, G. Wright, W. C. Chan et al., “The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma,” New England Journal of Medicine, vol. 346, no. 25, pp. 1937–1947, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. G. Wright, B. Tan, A. Rosenwald, E. H. Hurt, A. Wiestner, and L. M. Staudt, “A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 17, pp. 9991–9996, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. G. W. Van Imhoff, E. J. G. Boerma, B. Van Der Holt et al., “Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4135–4142, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. G. Lenz, G. Wright, S. S. Dave et al., “Stromal gene signatures in large-B-cell lymphomas,” New England Journal of Medicine, vol. 359, no. 22, pp. 2313–2323, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. C. P. Hans, D. D. Weisenburger, T. C. Greiner et al., “Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray,” Blood, vol. 103, no. 1, pp. 275–282, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. W. W. L. Choi, D. D. Weisenburger, T. C. Greiner et al., “A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy,” Clinical Cancer Research, vol. 15, no. 17, pp. 5494–5502, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. H. Nyman, M. Jerkeman, M. L. Karjalainen-Lindsberg, A. H. Banham, and S. Leppä, “Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP,” Modern Pathology, vol. 22, no. 8, pp. 1094–1101, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. G. Ott, M. Ziepert, W. Klapper et al., “Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL,” Blood, vol. 116, no. 23, pp. 4916–4925, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. J. P. Jais, C. Haioun, T. J. Molina et al., “The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab,” Leukemia, vol. 22, no. 10, pp. 1917–1924, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. C. Thieblemont, J. Briere, N. Mounier et al., “The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study,” Journal of Clinical Oncology, vol. 29, no. 31, pp. 4079–4087, 2011. View at Publisher · View at Google Scholar · View at PubMed
  58. K. Gu, D. D. Weisenburger, K. Fu et al., “Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation,” Hematological Oncology. In press. View at Publisher · View at Google Scholar · View at PubMed